In 9MFY19, revenue from operations improved by 17 per cent to ₹ 5,762 crore
Aster DM Healthcare announced its financial results for the quarter and nine months ended December 31, 2018. Revenue from operations for Q3FY19 was up by 19 per cent to ₹ 2,150 crore as against ₹ 1,814 crore in Q3FY18. EBITDA was up by 54 per cent to ₹ 263 crore from ₹ 172 crore in Q3 FY18. PAT adjusted for the exceptional income in previous year grew by 42 per cent from ₹ 71 crore in Q3FY18 to ₹ 100 crore in current quarter.
The company’s strong growth is a reflection of its focus on quality healthcare, the strength of its diversified healthcare offerings and a strong thrust on enhancing efficiencies.
In Q3FY19, revenue from operations improved by 19 per cent to ₹ 2,150 crore compared to
₹ 1,814 crore Q3FY18. EBITDA (excluding other income) increased by 54 per cent Y-o-Y to ₹ 263 crore compared to ₹ 172 crore. PAT, adjusted for exceptional income in previous year, increased to ₹ 100 crore compared to ₹ 71 crore.
In 9MFY19, revenue from operations improved by 17 per cent to ₹ 5,762 crore compared to
₹ 4,937 crore in 9MFY18. EBITDA, excluding other income, grew by 47 per cent Y-o-Y to ₹ 513 crore compared to ₹ 350 crore. PAT, adjusted for exceptional income in previous year, increased to ₹ 125 crore compared to loss of ₹ 6 crore
Commenting on the performance for Q3 and 9MFY19, Dr Azad Moopen, Chairman, Aster DM Healthcare, said, “We are happy with our performance growth in a quarter wherein seasonality plays to our advantage. We have done well both sequentially and on a corresponding quarter basis. Our business in India is growing well and we are making progress here. Our expansion in our brand across geographies will definitely help our global foot print. Our strategy here is to work on setting up two hospital every year and gradually increasing the capacity utilisation. Over a period of time we also strongly believe that the Ayushman Bharat scheme will give opportunities for some of our businesses in tier 2 cities. The GCC businesses also holds strong especially with majority of the geographies moving towards mandatory insurance. With major part of the financial year gone by and our performance positively reflected in our results, we are confident on ending the year on a strong note with a strong focus on clinical excellence and expansion.”
- Advertisement -